anti-exenatide antibodies: safety, eﬃ   cacy and cross-reactivity with long-term treatment. Diabetes Obes Metab 2012; 14: 546–54.  27 Bunck MC, Diamant M, Corner A, et al. One-year treatment with  exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009; 32: 762–68.  28 Rosenstock J. Basal insulin supplementation in type 2 diabetes;  reﬁ  ning the tactics. Am J Med 2004; 116 (suppl 3A):  10S–16S.  29 Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic,  prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716–30.  30 Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of  hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364–79.